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ABSTRACT
A study was conducted to investigate the antiviral activity of aqueous extracts from Orthosiphon stamineus (OS). 
Extraction was done using different parts of OS. The whole plant except root (WPOS), leaves (LOS) and flowers (FOS) of 
OS were extracted using aqueous extraction method. Cytotoxicity was assessed using 3-(4,5-dimethylthiazol-2,5-diphenyl 
tetrazolium bromide (MTT) assay. Plaque reduction assays were carried out to evaluate the antiviral activity of OS extract 
against herpes simplex virus type 1 (HSV-1). These include post-treatment, pre-treatment and virucidal assays. High 
antiviral activity was observed in post-treatment and virucidal assay with 100% reduction of HSV-1 plaque at 0.39 mg/
mL in LOS, FOS and WPOS. In pre-treatment assay, 79%, 84% and 97% plaque reduction using the same concentration 
was observed in FOS, LOS and WPOS, respectively. In conclusion, this study showed that OS aqueous extract has promising 
potential to be explored as anti-HSV-1 agent regardless of the mode of treatment.
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ABSTRAK
Suatu kajian telah dijalankan untuk menguji aktiviti antivirus bagi ekstrak akuas daripada Orthosiphon stamineus 
(OS). Pengekstrakan telah dijalankan dengan menggunakan bahagian OS yang berbeza. Seluruh tumbuhan kecuali akar 
(WPOS), daun (LOS) dan bunga (FOS) OS telah diekstrak melalui kaedah pengekstrakan akues. Ujian kesitotoksikan telah 
dijalankan dengan asai 3-(4,5- dimetiltiazol-2,5-diphenil tetrazolium bromida (MTT). Asai pengurangan plak telah 
dilakukan untuk mengkaji aktiviti antivirus ekstrak OS terhadap virus herpes simpleks jenis 1 (HSV-1). Antaranya ialah 
asai pasca-rawatan, pra-rawatan dan virusid.  Aktiviti antivirus yang tinggi telah diperhatikan dalam asai virusid dan 
pasca-rawatan dengan 100% pengurangan plak HSV-1 pada 0.39 mg/mL bagi LOS, FOS dan WPOS. Dalam pra-rawatan, 
sebanyak 79%, 84% dan 97% pengurangan plak pada kepekatan ekstrak yang sama telah dicerap masing-masing dalam 
FOS, LOS dan WPOS. Secara keseluruhan, kajian ini telah menunjukkan bahawa ekstrak OS mempunyai potensi yang tinggi 
untuk dieksplotasi sebagai agen anti-HSV-1 tanpa mengira mod rawatan.
Kata kunci: Asai pengurangan plak; etnofarmakologi; kesitotoksikan; MTT;  virusid
INTRODUCTION
Orthosiphon stamineus or misai kucing is one of the 
unique medicinal herbs which has been reported to exert 
dynamic pharmacological properties not only traditionally 
but also scientifically proven. Extract of OS has been 
reported to exhibit comparable antioxidant activity with 
pure quercetin and synthetic antioxidant, BHA (Akowuah 
et al. 2005). Research by Al-suede et al. (2012) showed 
that OS also exhibited anti-tumour activity where OS extract 
significantly inhibited orthotopically implanted colon 
tumor in immunocompromised mouse xenograft model. 
In addition, OS extract also showed antibacterial activity 
against Vibrio parahaemolyticus, a food borne bacteria 
(Ho et al. 2010) and also antifungal properties against 
R. solani, B. cinerea, F. solani and Colletotricum capsisi 
(Amzad et. al 2007). 
 Herpes simplex virus (HSV) is a double-stranded DNA 
virus with a genome size of at least 152 kbp. The virion 
is made up of four major components which are the viral 
DNA, icosahedral capsid, tegument which surrounds the 
capsid and envelope (Roizman & Knipe 1993). The ability 
to invade and replicate in human central nervous system 
followed by establishment of latent infection are two 
unique biological properties of HSV and these biological 
properties enable reactivation of the latent virus (Whitley 
& Roizman 2001). Acyclovir (ACV), a synthetic acyclic 
purine nucleoside analogue has been widely prescribed for 
decades as a therapy for HSV infections and still available 
to date. However, there have been reports on ACV resistant 
strains in cases involving immunocompromised individual 
and this resistance occurs through mutations in the viral-
encoded thymidine kinase (TK) gene as well as on DNA 
polymerase loci (Schnipper & Crumpacker 1980; Whitley 
& Roizman 2001). In order to combat this resistant HSV-1 
strain, new antiviral agents with different mode of actions 
are indeed important.
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 Reported scientific research supported by empirical 
data has shown that OS has the potential in treating various 
ailments involving multiple organ illnesses, cancer and 
infection of pathogenic fungi and bacteria. However, to 
date none has reported on the aqueous extract activity of 
OS against virus. To the best of our knowledge, this will be 
the first study to report on antiviral activity of OS aqueous 
extract against HSV-1. Therefore, the aim of this study 
was to investigate the potential of OS aqueous extract as 
an antiviral agent against HSV-1 infection.
MATERIALS AND METHODS
 PLANT MATERIAL
Dried OS plant was supplied by Ladang Herba Ya’acob 
Berkat Enterprise, Bukit Katil, Melaka. 
CELL AND VIRUS
Vero cell from American Type Culture Collection (ATCC) 
CCL-81 was used for both cytotoxicity and antiviral test. 
Dulbecco’s Modified Eagle’s Medium (DMEM) (Sigma-
Aldrich, USA) supplemented with 5% fetal bovine 
serum (FBS) (Sigma- Aldrich, USA) was used for cell 
maintenance throughout the experiment. Clinical strain 
of HSV-1 used was obtained from the stock culture of 
Faculty Science and Technology, Universiti Kebangsaan 
Malaysia. Briefly, the virus was propagated in vero cells, 
harvested and titrated using plaque assay as described by 
Nguyen et al. (2005).
PREPARATION OF AQUEOUS EXTRACTS
Dried OS leaves, flowers and the whole parts of the plant 
(except root) were finely ground and then extracted using 
deionized water with a ratio of extract to water of 10:1 
according to the method used by Li (2000) with slight 
modification. The extract was boiled for 2 h. The extract 
was then centrifuged and stored at -20°C. Freeze dry 
technique was performed to lyophilize the extract. Three 
abbreviations used to represent OS extract, namely WPOS 
which refers to whole plant extract, FOS which refers to 
flower extract and LOS which refers to leaves extract. 
CYTOTOXICITY TEST
Cytotoxicity test was conducted based on Mossman 
(1983). Briefly, lyophilized extracts were dissolved 
in growth medium (DMEM with 5% FBS) with starting 
concentration of 10 mg/mL. Two-fold serial dilution 
was done on each extract until a final concentration 
of 0.005 mg/mL. Confluent Vero cells (2.0 × 104 cell/
well) grown in 96-well microtitre plate were treated 
with different concentrations of extract. After 48 h of 
incubation, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl 
tetrazolium bromide (MTT) was added into each well and 
was further incubated for 3 h. Excess MTT was removed 
and 100 μL of dimethylsulfoxide (DMSO) was added. The 
absorbance was measured at 540 nm by using microplate 
reader (Chromate 4300, Awareness Technology, USA). 
Percentage of cell viability was calculated and the CC50 
value was obtained directly from graph of cell population 
versus extract concentration.
ANTIVIRAL ASSAY
Antiviral assays composed of post-treatment, pre-treatment 
and virucidal assays. 
Post-treatment assay:  Vero cells (2.0×105 cell/well) were 
seeded into 12 well plate and incubated overnight. Upon 
confluency, cells were inoculated with 200 μL of virus at 
50 PFU (plaque forming unit). Cells were incubated for 
2 h to allow virus adsorption. After adsorption period, 
DMEM+methylcellulose was mixed with six concentrations 
of extracts and added into all test wells. For WPOS extract, 
the concentrations used were ranged between 0.0977 and 50 
mg/mL while for FOS and LOS extracts, the concentrations 
used were ranged between 0.01 and 0.39 mg/mL. Cells 
were then incubated for 48 h. After incubation, cells were 
stained using crystal violet and plaques were counted 
according to Dargan (1998). 
Pre-treatment assay:  Vero cells (2.0 × 105 cell/well) 
were seeded in 12 well plate and incubated overnight. 
Cells were pre-treated with six concentrations of extracts 
for 24 h before being removed and infected with 200 μL 
of virus at 50 PFU. For WPOS extract, the concentrations 
used were the same as in post-treatment assay. For FOS 
and LOS extracts, the concentrations used were 0.01, 0.02, 
0.05, 0.1, 0.2 and 0.39 mg/mL. After adsorption period, 
DMEM+methylcellulose was added and incubated for 48 h. 
After incubation, cells were stained using crystal violet 
and plaques were counted. Infected cells treated with 5 
μM acyclovir (ACV) was used as positive control while 
infected cells without treatment was used as negative 
control. Selective Index, SI (CC50/EC50 ratio) was used 
to determine OS efficiency as a potential antiviral agent. 
Virucidal assay:  This test was carried out based on Shogan 
et al. (2006). High virus titre (106 PFU) was exposed to 0.39 
mg/mL of extracts for 30, 60 and 90 min at 37°C. Virus with 
DMEM only was used as negative control. After incubation, 
all tubes were diluted and titrated based on Blaho et al. 
(2005). Percentage of titer reduction was calculated by 
subtracting virus titer of control with treated sample (virus 
exposed to extracts).
RESULTS
CYTOTOXICITY EVALUATION OF WPOS EXTRACT
The aim of cytotoxicity evaluation was to determine the 
cytotoxic concentration that kills 50% cell population 
which is known as CC50 value. This value is used to define 
the upper-limit which needs to be used in the subsequent 
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antiviral studies. In this assay, the CC50 value of WPOS 
extract was determined at 3.125 mg/mL. Figure 1 shows the 
percentage of cell population versus concentration of WPOS 
extract. Thus, maximum concentration that was used in the 
subsequent antiviral studies was fixed at 3.125 mg/mL.
ANTI-HSV-1 ACTIVITY OF WPOS
Plaque reduction assays were done to screen for anti-HSV-1 
activity using WPOS extract with different concentrations. 
Figure 2(A), 2(B) and 2(C) shows the percentage of 
plaque reduction in post-treatment, pre-treatment and 
virucidal assays, respectively. The results from post-
treatment assay showed that 100% plaque reduction was 
achieved at a minimum concentration of 0.39 mg/mL. In 
pre-treatment assay, more than 95% plaque reduction was 
observed at 0.39 mg/mL. For virucidal assay, 0.39 mg/
mL of WPOS extract was used since it showed more than 
95% plaque reduction both pre- and post-treatment assays. 
When HSV-1 was exposed to 0.39 mg/mL extract for 30, 
60 and 90 min, 100% plaque reduction was observed. This 
assay showed that, a minimum of 30 min time exposure 
of extract on virus was sufficient to gain 100% inhibition 
of HSV-1 plaque.
 CYTOTOXICITY EVALUATION OF FOS AND LOS 
EXTRACTS
Different plant parts might contribute to different degree 
of toxicity on cells. Therefore, CC50 value for FOS and LOS 
extracts were determined in order to get safe range for the 
subsequent antiviral tests. Maximum concentration of FOS 
and LOS extracts used was 5 mg/mL since WPOS extract 
have a CC50 of 3.125 mg/mL. This value was chosen to 
take into consideration that certain parts of the plants might 
harbor certain compounds that contribute to higher toxicity. 
In this assay, the CC50 for FOS extract was determined to be 
1.269 mg/mL. Lower concentration of CC50 was observed 
for LOS extract at 0.766 mg/mL (Figure 3).FIGURE 1. Effect of different concentration of WPOS extract towards the population of Vero cells
FIGURE 3. Effect of different concentration of FOS and LOS 
extracts towards population of Vero cells
ANTI-HSV-1 ACTIVITY OF FOS AND LOS EXTRACTS
Following anti-HSV-1 activity screening of WPOS extract, 
determination of specific part of the plant that contributed 
to the high antiviral activity observed was done. Figures 
4 and 5 show the results obtained from antiviral assays 
using FOS and LOS extracts, respectively. In post-treatment 
FIGURE 2. Antiviral activities of WPOS extract against HSV-1 via post-treatment assay 
(A), pre-treatment assay (B) and virucidal assay (C)
A B C
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assay, 100% plaque reduction was observed in both FOS 
and LOS extracts at the highest concentration (0.39 mg/mL) 
(Figures 4(A) and 5(A). The lowest concentration (0.01 
mg/mL) of both FOS and LOS still exhibited mild reduction 
which was less than 20%. For pre-treatment assay, both 
FOS and LOS showed high activity which was 79% and 
84%, respectively, at highest concentration (0.39 mg/mL) 
(Figures 4(B) and 5(B)). Both extracts also displayed mild 
antiviral activity with less than 20% plaque reduction at 
the lowest concentration. The antiviral activity of FOS and 
LOS were observed to be concentration dependent as the 
percentage of plaque reduction is reduced with reducing 
OS concentration. In virucidal assays, exposure of HSV-1 
to both FOS and LOS extracts at 0.39 mg/mL reduced 100% 
of virus titer at all time points (Figure 4(C) and 5(C)). 
This result confirms the high virucidal activity observed 
in WPOS extract.
 Effectiveness of certain compounds or extracts can 
be evaluated by using selective index (SI). The evaluation 
will take into account of the toxicity value as well as the 
antiviral concentration for specific cell line. Therefore, 
the SI was calculated for each part of OS in post-treatment 
and pre-treatment assay. Comparison of SI for all extracts 
between post-treatment and pre-treatment are shown 
in Tables 1 and 2. SI for post-treatment in all extracts 
showed high SI values compared to those obtained from 
pre-treatment assay.
TABLE 1. CC50, EC50 and SI values of all extracts 
in post-treatment
CC50 (mg/mL) EC50 (mg/mL) SI (CC50/EC50)
FOS 1.269 0.0735 17.27
LOS 0.844 0.044 19.18
WPOS 3.125 0.1953 16.00







FOS 1.269 0.325 3.9
LOS 0.844 0.183 4.6
WPOS 3.125 - -
DISCUSSION
Bioactive compound in plant refers to the secondary 
metabolites which elicit pharmacological or toxicological 
effects in different organisms. Plant secondary metabolites 
hold important functions in living plants such as in 
protecting the plants from harsh environment and 
in protecting systems (Bernhoft 2010). Based on 
phytochemical analyses, OS has been proven to be rich 
FIGURE 4. Antiviral activities of FOS extracts against HSV-1 via post-treatment assay 
(A), pre-treatment assay (B) and viruidal assay (C)
A B C
FIGURE 5. Antiviral activities of LOS extract against HSV-1 via post-treatment assay 
(A), pre-treatment assay (B) and virucidal assay (C)
A B C
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in secondary metabolites such as glycosides, phenolic 
compound such as lipophilic flavones, flavonol glycosides 
and caffeic acid derivatives (Sumaryono et al. 1991), 
mono-, di- and sesqui-terpenoids (Tezuka et al. 2000). 
Previously, phytochemical analysis using high performance 
liquid chromatography (HPLC) by Hussin et al. (2013) 
showed aqueous extract of OS leaves has various bioactive 
compounds such as phenolic acids (caffeic acid and 
rosmaarinic acid) and methoxylated flavones (sinensetin 
and eupatorin). Distribution of metabolites across different 
parts of the OS plant may contribute to the differences in 
toxicity profiles observed. This is in agreement with this 
study where different CC50 values were observed across 
WPOS, FOS and LOS extracts. The highest CC50 value was 
observed in WPOS extract followed by FOS and LOS extracts 
which indicates using whole plant extract is more toxic 
compared to using separate parts of the plant. Lyu et al. 
(2005) showed that flavanols, flavanones, isoflavones and 
flavonols inhibit HSV-1 in vitro via plaque reduction assay. 
Leaves of OS have been reported by many researchers to 
be rich in flavonoid (Akowuah et. al 2004; Al-Suede et. 
al 2012; Hossain et al. 2013; Hussin et al. 2015). Thus, 
the richness of flavonoid in OS leaves may contribute to 
anti-HSV-1 properties. Therefore, we hypothesized that OS 
exerts antiviral activity which lead us to screen the whole 
plant for its anti-HSV-1 activity.
 In this study, antiviral screening was initially done on 
whole plant to evaluate the antiviral efficacy. High activity 
shown by whole plant has prompted us to further study this 
plant by evaluating the antiviral efficacy by different parts 
of the plant. Identifying the actual plant parts with high 
antiviral activity, will enable us to focus and maximize the 
antiviral activity study towards respected parts without 
wasting the whole plant.
 When virus infects a cell, it causes morphological 
changes to the cell. In HSV-1 infection, it causes 
enlargement of cells from its original size which is 
known as cytopathic effect (CPE). However, when HSV-1 
completed its replication cycle, it egresses from the cell 
by lysis to release the virus progeny. The lysis of cells 
caused by viral egression leaves a gap which is known as 
plaque. The progeny will then infect the surrounding cells 
and the process repeats, making the gap/plaque bigger. 
These are the basis of antiviral efficacy evaluation where 
inhibition of plaque indicates the inhibition of virus. The 
antiviral activity of WPOS, FOS and LOS extract were studied 
in the context of three main treatments which are post-, 
pre- and virucidal effect using plaque reduction assay. 
Plaque reduction assay is a quantitative measurement of 
the number of plaques that are formed by a virus at various 
dilutions (Smither et al. 2013).
 Post-treatment was given after the adsorption of 
the virus onto the cell. Thus this assay was done to 
investigate the activity of the extracts in inhibiting viral 
replication cycle downstream of the HSV-1 entry process. 
The inhibition may exert at various stages of the viral 
replication cycle such as during the transcription of 
viral genes (immediate early gene, early gene, genome 
replication or late gene expression), envelopment process 
or during egression (Whitley et al. 1998). Pre-treatment 
was done to study the effect of the extract as prophylactic 
agent in protecting the cell from HSV-1 adsorption and 
penetration. Therefore, inhibition by OS indicates that 
the extract can act as prophylactic agent to protect Vero 
cells against HSV-1 infection. The ability of the extract to 
act directly against HSV-1 virion particle was observed 
in virucidal assay. High titre of HSV-1 was challenged 
with specific concentration of OS extract. OS extract was 
observed to have 100% inhibition of HSV-1 infection 
regardless of duration of treatment. Titer reduction 
observed in virucidal assay might be due to direct effect of 
extract towards HSV-1 envelope or glycoproteins that lead 
to the failure of HSV-1 virion particles to adsorb and enter 
the cell after being exposed to OS. The same finding was 
reported by Schumacer et al. (2003). They demonstrated 
that peppermint oil extract has the ability to inhibit HSV-1 
plaque formation in virucidal assay and they concluded that 
free HSV-1 particles are very sensitive towards the extract.
 Both leaves and flower (LOS and FOS, respectively) 
showed high anti-HSV-1 activity. Post-treatment of OS 
has the potential to be exploited where the SI values were 
more than 10 in all extracts. Antiviral agent with SI value 
of more than 10 can be considered to possess high potential 
to be developed as antiviral (Dargan 1998). However, the 
results of SI for pre-treatment in all three extracts suggest 
that they are not suitable to be used as prophylactic agents. 
Although commercial antiviral drugs such as acyclovir, 
penciclovir, valaciclovir and foscarnet have high SI value 
and are major regimes for anti-HSV-1 treatments, they do 
not exert virucidal activity against HSV-1 (Arvin et al. 
2007). It is a big advantage for an antiviral drug to exhibit 
virucidal activity as well, as it would directly affect the 
virus without affecting the cells. It is also important to have 
antiviral drugs that possess different antiviral mechanisms 
as HSV-1 has conferred resistant towards currently available 
commercial drugs.
 A commercially available herbal medicine known 
as Setarud (IMODTM) that has been used intravenously to 
treat human immunodeficiency virus (HIV) was proven to 
inhibit HSV-1 by virucidal effect (Zabihollahi et al. 2012). 
However, the inhibition percentage of this herbal medicine 
(54%) was lower than that of OS extracts which shows 
100% inhibition. Collectively, OS extracts showed ability 
in different type of antiviral treatments unlike commercial 
drugs which usually only focus on one treatment.
CONCLUSION
This study demonstrates the ability of O. stamineus 
aqueous extract as a novel anti-HSV-1 agent via post-
treatment, pre-treatment as well as virucidal assay. All the 
conducted assays proved high percentage of plaque and 
viral titre reduction in infected cells after exposure to the 
extracts. LOS exhibited lower cytotoxicity compared to the 
other two extracts. This implies that LOS might be more 
suitable to be used as a long-term regime in combating HSV-
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1 infection. Although plaque reduction assays exhibited 
promising antiviral properties of OS extracts, further studies 
are required to explore the underlying mechanisms that 
contribute to its antiviral activity. 
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